secwatch.observer — SEC 8-K summary
======================================

Issuer:     FEMASYS INC (FEMY)
CIK:        0001339005
Form:       8-K
Filed at:   2024-03-06T23:59:59+00:00
Accession:  0001140361-24-011613
Event type: other_material
Sentiment:  positive
Materiality: 0.55
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Femasys completes first in-office commercial FemaSeed infertility procedure
---------------------------------------------------------------------------

- First commercial procedure using FDA-cleared FemaSeed intratubal insemination performed in Saginaw, Michigan.
- CEO cites FemaSeed as cost-effective, safer alternative to IVF amid Alabama Supreme Court frozen embryo ruling.
- Top-line pivotal data from FemaSeed study expected to be announced in Q1 2024.
- Procedure conducted by Dr. Andrew Wagner of Women's OB-GYN PC.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1339005/000114036124011613/0001140361-24-011613-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1339005/000114036124011613/ef20023361_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-24-011613

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer